Extending Clinical Equipoise to Phase 1 Trials Involving Patients: Unresolved Problems
Anderson, James A
Kennedy Institute of Ethics journal 2010 Mar ; 20(1): 75-98
Notwithstanding requirements for scientific/social value and risk/benefit proportionality in major research ethics policies, there are no widely accepted standards for these judgments in Phase 1 trials. This paper examines whether the principle of clinical equipoise can be used as a standard for assessing the ratio of risk to direct-benefit presented by drugs administered in one category of Phase 1 study--first-in-human trials involving patients. On the basis of the supporting evidence for, and architecture of, Phase 1 studies, the articles offers two provisional conclusions: (1) the risks of drug administration in such trials cannot generally be justified on therapeutic grounds but by appeal to the social value of the research; and (2) a framework for adjudicating the ratio of risk/social-value must be developed.
Showing items related by title, author, creator and subject.
Kimmelman, Jonathan (2007-12)Relatively little has been written about the ethics of conducting early phase clinical trials involving subjects from the developing world. Below, I analyze ethical issues surrounding one of gene transfer's most widely ...
Elements of style: consent form language and the therapeutic misconception in phase 1 gene transfer trials Kimmelman, Jonathan; Levenstadt, Aaron (2005-04)The therapeutic misconception arises wherever human subjects misinterpret the primary purpose of a clinical trial as therapeutic. Such misconceptions are particularly prevalent in trials involving severely ill subjects or ...
Cheng, Jonathan D.; Hitt, James; Koczwara, Bogda; Schulman, Kevin A.; Burnett, Caroline B.; Gaskin, Darrell J.; Rowland, Julia H.; Meropol, Neal J. (2000-01)